Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia

被引：6

作者：

Venton, G. ^{[1
,2
,3
]}

Adam, H. ^{[7
]}

Colle, J. ^{[1
,2
,3
]}

Labiad, Y. ^{[1
,2
]}

Mercier, C. ^{[3
,4
,5
]}

Ivanov, V. ^{[3
]}

Suchon, P. ^{[6
]}

Fanciullino, R. ^{[4
,5
,7
]}

Farnault, L. ^{[3
]}

Costello, R. ^{[1
,2
,3
]}

机构：

[1] INSERM, UMR1090, TAGC, F-13288 Marseille, France

[2] Aix Marseille Univ, UMR1090, TAGC, F-13288 Marseille, France

[3] Hop Conception, AP HM, Serv Hematol & Therapie Cellulaire, Marseille, France

[4] INSERM, Lab Toxicocinet & Pharmacocinet, Fac Pharm, UMR 911, Marseille, France

[5] Hop La Timone, AP HM, Lab Hematol, Marseille, France

[6] INSERM, UMR 1062, NORT, Marseille, France

[7] Hop Conception, Unite Pharm Hosp, Marseille, France

来源：

MEDECINE ET MALADIES INFECTIEUSES | 2016年 / 46卷 / 04期

关键词：

Micafungin; Acute myeloid leukemia; Aspergillus; INVASIVE FUNGAL DISEASES; CANDIDA-GLABRATA; CHEMOTHERAPY; CASPOFUNGIN; CANCER;

D O I：

10.1016/j.medmal.2016.03.008

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objective. - To study the efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing induction chemotherapy for acute myeloid leukemia. Patients and methods. - A prospective observational single-center study of 41 patients from the hematology department between May 2012 and April 2015. Micafungin was administered once daily from the first day of induction chemotherapy to the end of the neutropenic phase. Results. - Neither Candida nor Aspergillus infection was documented in our 41 patients from the first day of micafungin infusion to the end of the neutropenic phase. Patients were followed for three months after discontinuation of micafungin and none of them contracted an invasive fungal infection. Only one patient presented with grade hepatic and ionic toxicities. Conclusion. - Micafungin is associated with a good safety profile and is an interesting option for preventing invasive fungal infections in the high-risk population of patients presenting with hematological disorders. (C) 2016 Elsevier Masson SAS. All rights reserved.

引用

页码：226 / 229

页数：4

共 16 条

[1] Optimizing antifungal choice and administration [J].

Andes, David .

CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 :13-18

[2] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].

Ascioglu, S ;

Rex, JH ;

de Pauw, B ;

Bennett, JE ;

Bille, J ;

Crokaert, F ;

Denning, DW ;

Donnelly, JP ;

Edwards, JE ;

Erjavec, Z ;

Fiere, D ;

Lortholary, O ;

Maertens, J ;

Meis, JF ;

Patterson, TF ;

Ritter, J ;

Selleslag, D ;

Shah, PM ;

Stevens, DA ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14

[3] A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study) [J].

Cattaneo, Chiara ;

Monte, Simona ;

Algarotti, Alessandra ;

Audisio, Ernesta ;

Borlenghi, Erika ;

Campiotti, Leonardo ;

Cerqui, Elisa ;

Fanizza, Caterina ;

Giuliani, Rachele ;

Mico, Caterina ;

Rocconi, Roberta ;

Salvi, Anna ;

Salvi, Flavia ;

Verga, Luisa ;

Levis, Alessandro ;

Deliliers, Giorgio Lambertenghi ;

Pogliani, Enrico M. ;

Tognoni, Gianni ;

Rambaldi, Alessandro ;

Rossi, Giuseppe .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (09) :2140-2145

[4] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].

Cornely, Oliver A. ;

Maertens, Johan ;

Winston, Drew J. ;

Perfect, John ;

Ullmann, Andrew J. ;

Walsh, Thomas J. ;

Helfgott, David ;

Holowiecki, Jerzy ;

Stockelberg, Dick ;

Goh, Yeow-Tee ;

Petrini, Mario ;

Hardalo, Cathy ;

Suresh, Ramachandran ;

Angulo-Gonzalez, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359

[5] Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia [J].

Desplanques, P. -Y. ;

Burlacu, R. ;

Poinsignon, V. ;

Boussion, H. ;

Borget, I. ;

Wyplosz, B. ;

de Botton, S. ;

Billaud, E. ;

Chachaty, E. ;

Gachot, B. ;

Netzer, F. ;

Micol, J. -B. .

MEDECINE ET MALADIES INFECTIEUSES, 2014, 44 (04) :174-179

[6] Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials [J].

Ethier, M. C. ;

Science, M. ;

Beyene, J. ;

Briel, M. ;

Lehrnbecher, T. ;

Sung, L. .

BRITISH JOURNAL OF CANCER, 2012, 106 (10) :1626-1637

[7] Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia [J].

Girmenia, Corrado ;

Micozzi, Alessandra ;

Piciocchi, Alfonso ;

Gentile, Giuseppe ;

Di Caprio, Luigi ;

Nasso, Daniela ;

Minotti, Clara ;

Capria, Saveria ;

Cartoni, Claudio ;

Alimena, Giuliana ;

Meloni, Giovanna ;

Amadori, Sergio ;

Foa, Robin ;

Venditti, Adriano .

LEUKEMIA RESEARCH, 2014, 38 (04) :469-474

[8] European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update [J].

Maertens, J. ;

Marchetti, O. ;

Herbrecht, R. ;

Cornely, O. A. ;

Flueckiger, U. ;

Frere, P. ;

Gachot, B. ;

Heinz, W. J. ;

Lass-Floerl, C. ;

Ribaud, P. ;

Thiebaut, A. ;

Cordonnier, C. .

BONE MARROW TRANSPLANTATION, 2011, 46 (05) :709-718

[9] Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies [J].

Mattiuzzi, GN ;

Alvarado, G ;

Giles, FJ ;

Ostrosky-Zeichner, L ;

Cortes, J ;

O'Brien, S ;

Verstovsek, S ;

Faderl, S ;

Zhou, X ;

Raad, II ;

Bekele, BN ;

Leitz, GJ ;

Lopez-Roman, I ;

Estey, EH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :143-147

[10]

Nachbaur D, 2014, EUR J HAEMATOL, V94, P261

← 1 2 →